USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
21ST CENTURY THERAPEUTICS, INC.
Address:
52623 SEVEN OAKS DR
SHELBY TOWNSHIP, MI 48316-2990
Phone:
N/A
URL:
N/A
EIN:
138331643
DUNS:
968109702
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $341,709.00 2
SBIR Phase II $1,133,678.00 1

Award List:

Novel Small-molecule TNF-a Modulators as Chemoprotective Agents

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$154,852.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprote ctive agent which reduces the side effects… More

Novel small-molecule TNF-a modulators as chemoprotective agents

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,133,678.00
Agency:
HHS
Principal Investigator:
Jiajiu Shaw – 313-870-1741
Abstract:
DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepatotoxicity and myelosuppression. Therefore, a chemoprotective agent which reduces the side effects… More

TAS::75 0849::TAS

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$186,857.00
Agency:
HHS
Principal Investigator:
Jiajiu Shaw – 313-874-6798
Abstract:
Radiotherapy can potentially inflict serious damage on healthy normal organs. For example, pneumonitis and fibrosis are two well-recognized adverse effects from lung cancer radiotherapy: Currently, amifostine (Ethyol) is the only approved radioprotector indicated to reduce xerostomia associated with… More